NCT05011526View on ClinicalTrials.gov

A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults

PHASE3CompletedINTERVENTIONAL
Enrollment

1,030

Participants

Timeline

Start Date

October 8, 2021

Primary Completion Date

December 28, 2021

Study Completion Date

May 21, 2022

Conditions
Covid19 Vaccine
Interventions
BIOLOGICAL

MVC-COV1901

Approximately 471 participants will receive 2 doses of MVC-COV1901(S-2P protein with adjuvant) at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region

BIOLOGICAL

AZD1222

Approximately 471 participants will receive 2 doses of AZD1222 at Day 1 and Day 29 via intramuscular (IM) injection in the deltoid region

Trial Locations (2)

Unknown

Hospital Fundación Tesai, Ciudad del Este

Hospital de Clinicas - Facultad de Ciencias Médicas, Universidad Nacional de Asunción, San Lorenzo

Sponsors
All Listed Sponsors
lead

Medigen Vaccine Biologics Corp.

INDUSTRY

NCT05011526 - A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 Against COVID-19 in Adults | Biotech Hunter | Biotech Hunter